Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Craig C. Parker M.B.A. | CEO, President & Director | 825.32k | -- | 1962 |
| Mr. Charles Williams | CFO, COO & Corporate Secretary | 611.03k | -- | 1980 |
| Dr. Li Yang Ph.D. | Executive Vice President of Research | 535.46k | -- | 1969 |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisory Board | -- | -- | -- |
| Dr. Roeland Nusse Ph.D. | Co-Founder & Member of Scientific Advisory Board | -- | -- | 1950 |
| Dr. Calvin Kuo M.D., Ph.D. | Co-Founder & Member of Scientific Advisor | -- | -- | -- |
| Esther Jhun | Controller | -- | -- | -- |
Surrozen, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 42
Description
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
Corporate Governance
Upcoming Events
November 6, 2024 at 9:05 PM UTC
Surrozen, Inc. Earnings Date